Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.

Juvenile idiopathic arthritis (JIA), a type of arthritis commonly occurring in children, is a chronic, inflammatory condition ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

The instinct to protect and secure a child’s future—especially when it comes to their health—is one of the deepest and most ...

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...

ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...